Gemcitabine and carboplatin treatment in advanced NSCLC: A retrospective evaluation including elderly patients

Roberto Murialdo, Davide Boy, Francesca Bertolotti, Maria Cristina Martini, Gisella Pastorino, Giorgio Sogno, Matteo Vallauri, Lorenza Moraglio, Lucia Tixi, Isabella Angelini, Vittoria Saccà, Alberto Ballestrero, Fulvio Brema

Research output: Contribution to journalArticlepeer-review


Background. Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer. Methods. Eighty-three patients with stage III-1V non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m 2 on days 1 and 8 every 21 days. Results. The overall response rate was 43.4%. Results obtained from elderly and non- elderly groups were compared using the logrank method. Median overall survival and progression-free survival were 11 and 7 months, respectively (12 and 7 months, non- elderly group; 6.5 and 5 months, elderly group, P = 0.28 and 0.25 respectively). Grade 3-4 toxicity included neutropenia, thrombocytopenia, anemia, nausea/vomiting, and diarrhea. Incidences of grade 3-4 toxicity were similar for elderly and non-elderly patients. Conclusions. Data confirm that carboplatin-gemcitabine is an active and well-tolerated regimen in advanced non-small cell lung cancer and could be investigated in elderly patients.

Original languageEnglish
Pages (from-to)36-42
Number of pages7
Issue number1
Publication statusPublished - Jan 2009


  • Carboplatin
  • Chemotherapy
  • Elderly
  • Gemcitabine
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Gemcitabine and carboplatin treatment in advanced NSCLC: A retrospective evaluation including elderly patients'. Together they form a unique fingerprint.

Cite this